1 ETF to Buy Before the End of the Year and 1 to Sell

NYSE: BKLN | Invesco Senior Loan ETF News, Ratings, and Charts

BKLN – Fed Chair Jerome Powell has assured a slowdown in rate hikes might commence in December. Benchmark indices gained substantially over the Fed Chair’s comments. Moreover, broader market gains from a Santa Claus rally are expected. Therefore, investors could consider buying the quality ETF Invesco Senior Loan (BKLN) before the end of the year. However, ARK Innovation (ARKK) might be best avoided now. Keep reading….

The Fed is expected to keep hiking rates till it achieves the target inflation rate of 2%. However, the pace of such hikes is scheduled to drop eventually. Fed Chair Jerome Powell recently stated that the central bank could start moderating the pace of rate increases as soon as the December meeting.

He added, “We don’t want to overtighten, so that’s why we are slowing down, and we are going to find our way to where the right level is.” Benchmark indices gained substantially over Powell’s assurance.

The S&P 500 gained 3%, and the Dow Jones Industrial Average gained 2.6% yesterday. Provided this momentum persists, markets could witness a sustained rally in December.

Moreover, the Santa Claus rally is further expected to boost the broader markets. According to the Stock Trader’s Almanac, the average Santa rally has boosted the S&P 500 by 1.3% since 1969.

Given the backdrop, investors could consider buying quality ETF Invesco Senior Loan ETF (BKLN) before the end of the year. However, ARK Innovation ETF (ARKK) might be best avoided now.

ETF to Buy:

Invesco Senior Loan ETF (BKLN)

BKLN invests in leveraged loans in the high-yield bond space. It invests entirely in U.S. leveraged loans, giving investors a pure play on the domestic economy.

With $4.04 billion in assets under management (AUM), BKLN’s top holdings include Short Term Investments Trust Government & Agency Portfolio Institutional, with a 17.97% weighting in the fund, followed by CORPORATE BOND at 3.20%, and Mozart Borrower Lp Term Loan B 15-Sep-2028 at 1.54%.

It currently has 130 holdings in total. Over the past month, the ETF’s net inflows were $366.67 million.

BKLN pays a $0.86 annual dividend, which yields 4.17% at the prevailing share price. Its four-year average dividend yield stands at 4.03%. Its dividends have increased at a marginal CAGR over the past five years. BKLN has gained marginally over the past month.

It is no surprise that BKLN has an overall A rating, which equates to Strong Buy in our proprietary POWR Ratings system.

In addition, it has an A grade for Trade, Buy & Hold, and Peer. BKLN is ranked #3 out of 58 ETFs in the B-rated High Yield Bond ETFs group. Click here to see all the BKLN ratings.

ETF to Avoid:

ARK Innovation ETF (ARKK)

ARKK is the flagship actively-managed fund from the team at ARK Invest, Cathie Wood’s advisory firm. It primarily profits from artificial intelligence, DNA technologies, energy innovation, automation, financial technology, and cloud computing industries.

With $7.15 billion in AUM, ARKK’s top holdings include Zoom Video Communications, Inc. Class A (ZM) with an 8.84% weighting, followed by Tesla, Inc. (TSLA) at 8.05%, and Roku, Inc. Class A (ROKU) at 7.33%. It has 32 holdings in total.

Over the past week, ARKK’s net outflows were $38.93 million. Its 0.75% expense ratio is higher than the 0.50% category average. Over the past month, ARKK has lost 3.6%.

ARKK has an overall F rating, equating to a Strong Sell in our POWR Ratings system. It has an F grade for Trade and Buy & Hold and a D for Peer. It is ranked #80 out of 118 ETFs in the D-rated Technology Equities ETFs group. Click here for all the ARKK ratings.


BKLN shares were unchanged in premarket trading Thursday. Year-to-date, BKLN has declined -2.11%, versus a -13.17% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
BKLNGet RatingGet RatingGet Rating
ARKKGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

The WORST Stock Market Ever!

It’s been a while since I talked to anyone enjoying the recent stock market action. Too volatile. Too illogical. No real trend. All true. However, the more we understand why this is happening the easier to diagnose what will happen from here and how we can trade our way to profits. (Spoiler Alert) I am still bearish. Gladly I still see 7 timely trades to use to make money as the S&P 500 (SPY) heads lower from here. Read on below for the full story…

:  |  News, Ratings, and Charts

This Software Stock Just Flashed a Buy Signal

Shares of cloud software maker Salesforce (CRM) have gained more than 40% over the past three months. Outstanding financial performance and a bullish outlook, with growing AI integration, have recently driven investor sentiment around CRM. Hence, this software stock might be an ideal buy considering its promising growth prospects and high profitability. Keep reading…

:  |  News, Ratings, and Charts

3 Stocks with More Upside Potential

Coupled with macroeconomic headwinds, the sudden regional banking failures have marred investor sentiments. Moreover, amid anticipations of a recession, the existing market volatilities are not likely to subside anytime soon. Given this backdrop, we think the strong growth prospects of Gilead Sciences (GILD), Teva Pharmaceutical (TEVA), and MacroGenics (MGNX) make these stocks wise portfolio additions now. Read on…

:  |  News, Ratings, and Charts

2 Top Stocks That Should Be on Your Radar This Spring

Amidst the turmoil in the banking sector, high inflation, and the Fed’s restrictive monetary policy, the economy faces a threat of recession this year. However, fundamentally strong stocks AbbVie (ABBV) and Salesforce (CRM) might be worth adding to your watchlist. Read more...

:  |  News, Ratings, and Charts

3 Stocks with More Upside Potential

Coupled with macroeconomic headwinds, the sudden regional banking failures have marred investor sentiments. Moreover, amid anticipations of a recession, the existing market volatilities are not likely to subside anytime soon. Given this backdrop, we think the strong growth prospects of Gilead Sciences (GILD), Teva Pharmaceutical (TEVA), and MacroGenics (MGNX) make these stocks wise portfolio additions now. Read on…

Read More Stories

More Invesco Senior Loan ETF (BKLN) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All BKLN News